AstraZeneca SEC Filings
NYSE: AZNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
159.20+0.42 (+0.26%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AstraZeneca filing overview
This page lists 60 recent SEC filings by AstraZeneca (AZN), including 53 6-K, 7 4. Form 10-K is the audited annual report, 10-Q the quarterly report, 8-K covers material events, and Form 4 reports insider transactions. All documents link directly to SEC EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
AZN SEC filings
| Filed | Form | Description | Document |
|---|---|---|---|
| Oct 8, 2026 | 4 | Statement of changes in beneficial ownership | View on EDGAR |
| Oct 5, 2026 | 6-K | ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT | View on EDGAR |
| Oct 2, 2026 | 6-K | AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY | View on EDGAR |
| Oct 1, 2026 | 6-K | TOTAL VOTING RIGHTS | View on EDGAR |
| Oct 1, 2026 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | View on EDGAR |
| Sep 29, 2026 | 6-K | ASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT | View on EDGAR |
| Sep 23, 2026 | 6-K | TRIXEO APPROVED IN EU FOR ASTHMA | View on EDGAR |
| Sep 21, 2026 | 6-K | ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC | View on EDGAR |
| Sep 21, 2026 | 6-K | KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP | View on EDGAR |
| Sep 18, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Sep 15, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Sep 15, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Sep 14, 2026 | 6-K | UPDATE ON SERENA-4 PHASE III TRIAL | View on EDGAR |
| Sep 11, 2026 | 4 | OWNERSHIP DOCUMENT | View on EDGAR |
| Sep 8, 2026 | 6-K | ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER | View on EDGAR |
| Sep 8, 2026 | 6-K | IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG | View on EDGAR |
| Sep 1, 2026 | 6-K | TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG | View on EDGAR |
| Sep 1, 2026 | 6-K | ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY | View on EDGAR |
| Sep 1, 2026 | 6-K | DIRECTORATE CHANGE | View on EDGAR |
| Sep 1, 2026 | 6-K | ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC | View on EDGAR |
| Sep 1, 2026 | 6-K | ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING | View on EDGAR |
| Sep 1, 2026 | 6-K | TOTAL VOTING RIGHTS | View on EDGAR |
| Sep 1, 2026 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | View on EDGAR |
| Aug 27, 2026 | 6-K | TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS | View on EDGAR |
| Aug 25, 2026 | 6-K | ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING | View on EDGAR |
| Aug 19, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| Aug 17, 2026 | 6-K | TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG | View on EDGAR |
| Aug 17, 2026 | 6-K | UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL | View on EDGAR |
| Aug 17, 2026 | 6-K | ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER | View on EDGAR |
| Aug 7, 2026 | 4 | Statement of changes in beneficial ownership | View on EDGAR |
| Aug 3, 2026 | 6-K | TOTAL VOTING RIGHTS | View on EDGAR |
| Aug 3, 2026 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | View on EDGAR |
| Jul 31, 2026 | 6-K | DATROWAY APPROVED IN EU FOR TNBC | View on EDGAR |
| Jul 27, 2026 | 6-K | Report of foreign private issuer | View on EDGAR |
| Jul 27, 2026 | 6-K | SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS | View on EDGAR |
| Jul 27, 2026 | 6-K | UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA | View on EDGAR |
| Jul 23, 2026 | 6-K | ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER | View on EDGAR |
| Jul 14, 2026 | 6-K | ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR | View on EDGAR |
| Jul 9, 2026 | 6-K | UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL | View on EDGAR |
| Jul 8, 2026 | 4 | OWNERSHIP DOCUMENT | View on EDGAR |
| Jul 1, 2026 | 6-K | TOTAL VOTING RIGHTS | View on EDGAR |
| Jul 1, 2026 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | View on EDGAR |
| Jun 29, 2026 | 6-K | DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC | View on EDGAR |
| Jun 29, 2026 | 6-K | ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS | View on EDGAR |
| Jun 16, 2026 | 4 | OWNERSHIP DOCUMENT | View on EDGAR |
| Jun 15, 2026 | 6-K | TRUQAP APPROVED IN US FOR PROSTATE CANCER | View on EDGAR |
| Jun 1, 2026 | 6-K | TOTAL VOTING RIGHTS | View on EDGAR |
| Jun 1, 2026 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | View on EDGAR |
| May 29, 2026 | 6-K | IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER | View on EDGAR |
| May 27, 2026 | 6-K | US FDA DECISION DATE ON CAMIZESTRANT EXTENDED | View on EDGAR |
| May 26, 2026 | 6-K | CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU | View on EDGAR |
| May 26, 2026 | 6-K | ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS | View on EDGAR |
| May 26, 2026 | 6-K | DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC | View on EDGAR |
| May 22, 2026 | 4 | OWNERSHIP DOCUMENT | View on EDGAR |
| May 18, 2026 | 6-K | ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS | View on EDGAR |
| May 18, 2026 | 6-K | BAXFENDY APPROVED IN THE US FOR HYPERTENSION | View on EDGAR |
| May 18, 2026 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View on EDGAR |
| May 14, 2026 | 6-K | IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER | View on EDGAR |
| May 8, 2026 | 4 | OWNERSHIP DOCUMENT | View on EDGAR |
| May 1, 2026 | 6-K | TOTAL VOTING RIGHTS AND ADMISSION OF SHARES | View on EDGAR |